Artidis AG is a clinical-stage health technology company founded as a spin-off from the Biozentrum and the Swiss Nanoscience Institute at the University of Basel. The company is developing a pioneering nanomechanical biomarker platform for cancer diagnosis and personalized treatment. Their ARTIDIS® technology, based on Atomic Force Microscopy (AFM), measures the physical properties of cells and tissues at the nanoscale. This allows for rapid and precise identification of cancer, assessment of its aggressiveness, and prediction of therapy response, aiming to empower clinicians with data-driven insights for better patient outcomes.
The Basel headquarters serves as the central hub for Artidis's research and development, clinical operations, corporate strategy, and global business management.
Located within Technopark Basel, providing access to a network of innovative companies, research institutions, and modern laboratory facilities. Its proximity to the University of Basel and major pharma companies fosters collaboration.
Artidis likely fosters a highly innovative, science-driven, and collaborative work environment. The culture emphasizes precision, cutting-edge research, and a strong focus on translating scientific breakthroughs into clinical applications to impact patient lives.
The headquarters' location in Basel is strategically important, leveraging Switzerland's world-class biotech ecosystem, access to talent, research collaborations, and a supportive regulatory environment for medical devices and diagnostics.
Artidis, while headquartered in Switzerland, operates with a global outlook. Its primary functions supported globally include collaborative research partnerships with international institutions, conducting multi-center clinical trials across different countries (e.g., pivotal studies in Europe), and engaging in business development activities to prepare for market entry in key regions such as Europe and North America. The ARTIDISnet platform is designed for potential global deployment in clinical settings.
Technopark Basel, Hochbergerstrasse 60C
Basel
Basel-Stadt
Switzerland
Address: One Broadway, 14th Floor, Cambridge, MA 02142 (Representative office/shared space example)
To facilitate engagement with the US Food and Drug Administration (FDA), connect with US-based research institutions and key opinion leaders, and expand Artidis's commercial footprint in the significant US healthcare market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ARTIDIS' leadership includes:
ARTIDIS has been backed by several prominent investors over the years, including:
Artidis has been strengthening its executive team to support its growth phase, particularly focusing on clinical development, business development, and preparing for commercialization. No major unexpected departures have been publicly noted, indicating team stability.
Discover the tools ARTIDIS uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Artidis AG likely uses standard corporate email formats. Common patterns include [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com]. Based on publicly available information and common practices for Swiss tech companies, these are the most probable formats.
[first].[last]@artidis.com or [f][last]@artidis.com
Format
marija.plodinec@artidis.com
Example
80%
Success rate
PR Newswire • February 28, 2024
Artidis announced the successful completion of patient recruitment for its ACD-BREAST pivotal clinical study. This marks a significant step in validating its nanomechanical biomarker technology for breast cancer diagnosis and therapy optimization, aiming to bring this innovation to patients....more
Artidis News • February 13, 2024
Artidis has strengthened its leadership team with the appointment of Dr. med. Sven Wellmann as Chief Medical Officer. Dr. Wellmann, a renowned expert in neonatology and pediatric oncology, will lead Artidis' clinical development and medical affairs....more
Artidis News / European Journal of Cancer • October 26, 2023
A study published in the European Journal of Cancer demonstrated the potential of Artidis's nanomechanical biomarkers to detect therapy resistance in breast cancer patient-derived organoids early on. This could enable timely adjustments to treatment strategies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ARTIDIS, are just a search away.